QuantaMatrix Q1 2026: Revenue Decline, Persistent Losses, and Management Control Change


  • Consolidated revenue KRW 726M, down 28.7% YoY from KRW 1,018M; net loss widened to KRW 4,970M (vs KRW 4,129M).
  • R&D expenses KRW 1,140M (145.8% of revenue); operating cash flow -KRW 4,920M.
  • Cash and equivalents KRW 13,000M (down from KRW 38,541M at year-end); total liquidity ~KRW 35B including short-term deposits.
  • Overseas sales of dRAST accounted for 76% of total revenue, with growth in Middle East (36%) and Asia (21%).
  • In Dec 2025, controlling shareholder and CEO signed an agreement to transfer management control to Pentastone 3 New Technology Investment Association (effective 15 months after payment), leading to expected board changes.
  • Convertible bonds outstanding: 2nd series KRW 17.5B (conversion price KRW 4,542) and 3rd series perpetual CB KRW 36B (conversion price KRW 4,329).
  • During the quarter, 114,100 new shares were issued upon conversion, bringing total shares to 20,135,029.
  • Key pipeline: uCIA (rapid blood culture/ID/AST system) and CARB-X funded neonatal sepsis diagnostic platform.

KOSDAQ Filing Information


  • Filing: Quarterly Report (2026.03)
  • Company: QuantaMatrix (317690)
  • Submission: QuantaMatrix Incorporated
  • Receipt: 05-15-2026